An evaluation of abrocitinib for moderate-to-severe atopic dermatitis

References

• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.
   PubMed Web of Science ®Google Scholar
• Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–590.
   PubMed Web of Science ®Google Scholar
• Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121(4):947–54.e915.
   PubMed Web of Science ®Google Scholar
• Dharmage SC, Lowe A, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17–27.
   PubMed Web of Science ®Google Scholar
• Shaker M. New insights into the allergic march. Curr Opin Pediatr. 2014;26(4):516–520.
   PubMed Web of Science ®Google Scholar
• Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105(2):99–106.
   PubMed Web of Science ®Google Scholar
• Kemp AS. Cost of illness of atopic dermatitis in children. Pharmacoeconomics. 2003;21(2):105–111.
   PubMed Web of Science ®Google Scholar
• Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25(1):1–6.
   PubMed Web of Science ®Google Scholar
• Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192–199.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Auziere S, Feldman SR, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–1036.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Curr Allergy Asthma Rep. 2008;8(4):306–311.
   PubMed Web of Science ®Google Scholar
• Williams HC. Atopic dermatitis. N Engl J Med. 2005;352(22):2314–2324.
   PubMed Web of Science ®Google Scholar
• Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013;70(1):3–11.
   PubMed Web of Science ®Google Scholar
• El Hachem M, Di Mauro G, Rotunno R, et al. Pruritus in pediatric patients with atopic dermatitis: a multidisciplinary approach-summary document from an Italian expert group. Ital J Pediatr. 2020;46(1):1–9.
   PubMed Web of Science ®Google Scholar
• Elmariah SB. Adjunctive management of itch in atopic dermatitis. Dermatol Clin. 2017;35(3):373–394.
   PubMed Web of Science ®Google Scholar
• Furue M, Yamamura K, Kido-Nakahara M, et al. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73(1):29–36.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Smith PK, Yosipovitch G. Mediators of Chronic Pruritus in Atopic Dermatitis: getting the Itch Out? Clin Rev Allergy Immunol. 2016;51(3):263–292.
   PubMed Web of Science ®Google Scholar
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360.
   PubMed Web of Science ®Google Scholar
• Frazier W, Bhardwaj N. Atopic dermatitis: diagnosis and treatment. Am Fam Physician. 2020;101(10):590–598.
   PubMedGoogle Scholar
• Weiss D, Nordhorn I, Tizek L, et al. prescription behaviour and barriers to prescription of biologicals for treatment of chronic inflammatory skin diseases in dermatological practice in two German Federal States. Acta Derm Venereol. 2021;101(9):adv00560.
   PubMedGoogle Scholar
• Lipman ZM, Labib A, Yosipovitch G. Current Clinical Options for the Management of Itch in Atopic Dermatitis. Clin Cosmet Investig Dermatol. 2021;14:959–969.
   PubMed Web of Science ®Google Scholar
• Goujon C, Viguier M, Staumont-Sallé D, et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase iii randomized noninferiority Trial. J Allergy Clin Immunol Pract. 2018;6(2):562–9.e563.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606–619.
   PubMed Web of Science ®Google Scholar
• Sroka-Tomaszewska J, Trzeciak M. Molecular mechanisms of atopic dermatitis pathogenesis. Int J Mol Sci. 2021;22:4130.
   PubMed Web of Science ®Google Scholar
• Furue M. Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 Axis: pathogenic and Therapeutic Implications in Atopic Dermatitis. J Clin Med. 2020;9(11):3741.
   Web of Science ®Google Scholar
• Furue M. Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic Implications in Atopic Dermatitis. Int J Mol Sci. 2020;21(15):5382.
   Web of Science ®Google Scholar
• Furue M, Ulzii D, Vu YH, et al. Pathogenesis of Atopic Dermatitis: current Paradigm. Iran J Immunol. 2019;16(2):97–107.
   PubMed Web of Science ®Google Scholar
• Liang HE, Reinhardt RL, Bando JK, et al. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol. 2011;13(1):58–66.
   PubMed Web of Science ®Google Scholar
• Bogiatzi SI, Fernandez I, Bichet JC, et al. Cutting Edge: proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. J Immunol. 2007;178(6):3373–3377.
   PubMed Web of Science ®Google Scholar
• Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022;71(1):40–46.
   PubMed Web of Science ®Google Scholar
• Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J Dermatol Sci. 2013;72(1):3–8.
   PubMed Web of Science ®Google Scholar
• Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J Am Acad Dermatol. 2018;78(3):S53–62.
   PubMed Web of Science ®Google Scholar
• Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927–940.
   PubMed Web of Science ®Google Scholar
• Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–77.e667.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Otsuka A, Nakashima C, et al. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model. J Dermatol Sci. 2020;97(2):161–164.
   PubMed Web of Science ®Google Scholar
• Ratchataswan T, Banzon TM, Thyssen JP, et al. Biologics for treatment of atopic dermatitis: current status and future prospect. J Allergy Clin Immunol Pract. 2021;9(3):1053–1065.
   PubMed Web of Science ®Google Scholar
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf. 2022 Feb 15.
   Google Scholar
• Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009.
   PubMed Web of Science ®Google Scholar
• Ariëns LFM, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. J Am Acad Dermatol. 2021;84(4):1000–1009.
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y. A literature review of real-world effectiveness and safety of dupilumab for atopic dermatitis. JID Innov. 2021;1(3):100042
   PubMedGoogle Scholar
• National Center for Biotechnology Information (2022). PubChem compound summary for CID 78323835. https://pubchem.ncbi.nlm.nih.gov/compound/Abrocitinib. 2022 Feb 15.
   Google Scholar
• Deeks ED, Duggan S. Abrocitinib: first Approval. Drugs. 2021;81(18):2149–2157.
   PubMed Web of Science ®Google Scholar
• Soto E, Banfield C, Gupta P, et al. Kinetic-pharmacodynamic model of platelet time course in patients with moderate-to-severe atopic dermatitis treated with oral janus kinase 1 inhibitor abrocitinib. CPT Pharmacometrics Syst Pharmacol. 2020;9(10):553–560.
   PubMedGoogle Scholar
• Wojciechowski J, Malhotra BK, Wang X, et al. Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib. Br J Clin Pharmacol. 2022;88(8):3856–3871.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase Ii and phase iii clinical trial program. Am J Clin Dermatol. 2021;22(5):693–707.
   PubMed Web of Science ®Google Scholar
• Peeva E, Hodge MR, Kieras E, et al. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: a phase 1, randomized, placebo-controlled, dose-escalation study. Br J Clin Pharmacol. 2018;84(8):1776–1788.
   PubMed Web of Science ®Google Scholar
• Kieras E, Zhang W, Banfield C, et al. PF-04965842, a JAK1 inhibitor, modulates pharmacodynamic and disease biomarkers in blood of atopic dermatitis patients. Paper presented at: EXPERIMENTAL DERMATOLOGY2018.
   Google Scholar
• Wang EQ, Le V, O’Gorman M, et al. Effects of Hepatic Impairment on the pharmacokinetics of abrocitinib and its metabolites. J Clin Pharmacol. 2021;61(10):1311–1323.
   PubMed Web of Science ®Google Scholar
• Wang EQ, Le V, Winton JA, et al. Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. J Clin Pharmacol. 2021;61(10):1311–1323.
   PubMed Web of Science ®Google Scholar
• Wojciechowski J, Malhotra BK, Wang X, et al. Population pharmacokinetics of abrocitinib in healthy individuals and patients with psoriasis or atopic dermatitis. Clin Pharmacokinet. 2022;61:709–723.
   PubMed Web of Science ®Google Scholar
• Wang X, Dowty ME, Wouters A, et al. Assessment of the effects of inhibition or induction of cyp2c19 and cyp2c9 enzymes, or inhibition of oat3, on the pharmacokinetics of abrocitinib and its metabolites in healthy individuals. Eur J Drug Metab Pharmacokinet. 2022;47(3):419–429.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–1379.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Wollenberg A, Bissonnette R, et al. Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib. Dermatitis. 2021;32(1S):S53–61.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–867.
   PubMed Web of Science ®Google Scholar
• Bieber T, Simpson EL, Silverberg JI, et al., Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12): 1101–1112.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Yosipovitch G, Paul C, et al. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022;36(3):434–443.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165–1173.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104–112.
   PubMed Web of Science ®Google Scholar
• Shi VY, Bhutani T, Fonacier L, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022;87(2):351–358.
   PubMed Web of Science ®Google Scholar
• Kim BS, Silverberg JI, Ständer S, et al., rapid improvement of itch associated with atopic dermatitis with abrocitinib is partially independent of overall disease improvement: results from pooled phase 2b and 3 monotherapy studies. Dermatitis. 2021;32(1S): S39–44.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Thyssen JP, Simpson EL, et al. Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes. Am J Clin Dermatol. 2021;22(4):541–554.
   PubMed Web of Science ®Google Scholar
• Cork MJ, McMichael A, Teng J, et al. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol. 2022;36(3):422–433.
   PubMed Web of Science ®Google Scholar
• Pereyra-Rodriguez JJ, Alcantara-Luna S, Domínguez-Cruz J, et al. Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis. Life (Basel). 2021;12(1):11.
   PubMedGoogle Scholar
• Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523–532.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Chu CY, Rojo R, et al. Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: results from JADE MONO-2 and JADE COMPARE. JAAD Int. 2021; 4: 46–48.
   PubMedGoogle Scholar
• UK’s MHRA grants marketing authorisation for pfizer’s cibinqo® (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis [ press release]. 2021.
   Google Scholar
• Approves Pfizer’s CIBINQO® JMHLW. (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis, press release, 2021
   Google Scholar
• European Commission Approves Pfizer’s Cibinqo® (abrocitinib). For the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis. 2021. press release. Available from: https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-cibinqor-abrocitinib#:~:text=(NYSE%3A%20PFE)%20today%20announced,are%20candidates%20for%20systemic%20therapy
   Google Scholar
• U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis. 2022. press release. Available from: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults
   Google Scholar
• Noda S, Suárez-Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–1264.
   PubMed Web of Science ®Google Scholar
• Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62–9.e61.
   PubMed Web of Science ®Google Scholar